Kuwentong Alzheimer At Iba Pa

07/02/2025

How to handle ‘wandering’

3M likes, 50.3K comments. “How would your life change if you became an expert, just like Debra? Take the Certified Master Dementia Strategist course. To apply, book a call at Www.answersaboutalz.org”

07/01/2025

🙏

Alzheimer's disease is a disorder of the brain that results in cognitive decline and is the main cause of dementia. Two types of early-stage Alzheimer's disease drugs were in practical use in Japan as of the end of 2024. We spoke about this with Iwatsubo Takeshi, a professor at the University of Tokyo's School of Medicine.

https://www3.nhk.or.jp/nhkworld/en/radio/asianview/interviews/202501031707/?cid=wohk-fb-org_site_asian_0103_mspr-202501-001
🎧Listen to the interview on "Asian View"

22/11/2024

♥️

10/09/2024

DEPRESSION
Approximately 280 million people worldwide suffer from depression, which affects all aspects of life and is a leading cause of su***de (1). Although traditional antidepressants (which act on monoamine neurotransmitters, such as serotonin and dopamine) can offer relief, they often take several weeks to become effective and many patients do not achieve sustained remission. Ketamine emerged as a revolutionary antidepressant owing to its rapid onset and sustained efficacy. Although ketamine is a noncompetitive blocker (antagonist) of N-methyl-D-aspartate receptor (NMDAR), the mechanisms by which it exerts its antidepressant effects remain unclear. On page 621 of this issue, Chen et al. (2) report that ketamine locks NMDARs in an inactive state, particularly in hyperactive neurons of the lateral habenula (LHb), blocking neuronal bursting activity and alleviating depressive symptoms in mice. The findings provide a mechanistic basis for ketamine’s rapid, region-specific, and sustained effects and could facilitate the design of improved antidepressants.

07/06/2024

A REMARKABLE NON-PHARMACOLOGIC WAY TO HANDLE DIFFICULT BEHAVIOR

01/03/2024

❤️